The Indian biotech company and Ocugen Inc have entered into a definitive agreement to co-develop, supply, and commercialise Covaxin for the US market. The company further agreed to pay to Bharat a milestone payment of USD 10 million within 30 days of the first commercial sale of Covaxin in Canada.
